Singapore markets closed

Takeda Pharmaceutical Company Limited (TAK)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
13.23-0.15 (-1.12%)
As of 10:53AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 41.77B
Enterprise value 69.85B
Trailing P/E 36.80
Forward P/E 23.31
PEG ratio (5-yr expected) 3.27
Price/sales (ttm)1.57
Price/book (mrq)0.96
Enterprise value/revenue 0.02
Enterprise value/EBITDA 0.07

Trading information

Stock price history

Beta (5Y monthly) 0.54
52-week change 3-20.40%
S&P500 52-week change 325.01%
52-week high 317.11
52-week low 313.11
50-day moving average 314.14
200-day moving average 314.61

Share statistics

Avg vol (3-month) 31.84M
Avg vol (10-day) 31.92M
Shares outstanding 53.14B
Implied shares outstanding 63.16B
Float 81.55B
% held by insiders 10.00%
% held by institutions 12.67%
Shares short (28 Mar 2024) 48.12M
Short ratio (28 Mar 2024) 45.26
Short % of float (28 Mar 2024) 4N/A
Short % of shares outstanding (28 Mar 2024) 40.26%
Shares short (prior month 29 Feb 2024) 46.26M

Dividends & splits

Forward annual dividend rate 40.64
Forward annual dividend yield 44.77%
Trailing annual dividend rate 3184.00
Trailing annual dividend yield 31,375.19%
5-year average dividend yield 44.72
Payout ratio 4158.21%
Dividend date 311 Dec 2023
Ex-dividend date 428 Sept 2023
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in JPY.

Fiscal year

Fiscal year ends 31 Mar 2023
Most-recent quarter (mrq)31 Dec 2023


Profit margin 4.28%
Operating margin (ttm)9.44%

Management effectiveness

Return on assets (ttm)2.61%
Return on equity (ttm)2.76%

Income statement

Revenue (ttm)4.17T
Revenue per share (ttm)1,335.47
Quarterly revenue growth (yoy)1.30%
Gross profit (ttm)N/A
Net income avi to common (ttm)178.22B
Diluted EPS (ttm)0.36
Quarterly earnings growth (yoy)-11.30%

Balance sheet

Total cash (mrq)288.36B
Total cash per share (mrq)183.79
Total debt (mrq)5.21T
Total debt/equity (mrq)77.21%
Current ratio (mrq)1.06
Book value per share (mrq)4,297.21

Cash flow statement

Operating cash flow (ttm)731.45B
Levered free cash flow (ttm)-9.88B